EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates Plus Immune Checkpoint Inhibitors for Sustained Disease Control in Advanced Solid Tumors

Meiling Xu, Jun Yin, Yao Li, Liyuan Zhang

Cancers · 06.11.2026 · 18 (21) · 3564

DOI: 10.3390/cancers18213564 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.11.2026. Verfasst von Meiling Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center of PRaG Therapy, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Radiology and Radiation Protection of Soochow University, New medical technology project of the Second Affiliated Hospital of Soochow University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) combined with immune checkpoint inhibitors (ICIs) improve outcomes in selected advanced solid tumors, but clinical benefit does not establish pharmacological synergy. This narrative review evaluates disease control during ADC–ICI therapy and the implications for radiotherapy in recurrent or metastatic disease. Prolonged disease control is assessed primarily through progression-free survival in randomized trials; response duration provides complementary evidence among responders. Overall survival, quality of life, and toxicity determine the broader clinical value of treatment. Randomized trials support specific regimens in urothelial, breast, and lung cancers, whereas negative studies argue against generalization across drugs and diseases. Antigen expression, payload delivery, and the immune microenvironment may contribute to heterogeneous outcomes, but their clinical roles remain incompletely established. Reported treatment durations do not define optimal stopping times. Radiotherapy can address local symptoms, but whether it improves systemic disease control during ADC–ICI therapy remains unproven. We distinguish direct three-modality evidence from indirect ADC–radiotherapy and ICI–radiotherapy studies and identify priorities for patient selection, outcome assessment, and safety monitoring. Current evidence supports regimen-specific treatment selection and toxicity-directed modification, not routine radiotherapy addition or elective drug withdrawal across disease settings.

Schlagwörter

Stichwörter der Autor:innen

advanced solid tumorsantibody–drug conjugatesdisease controlimmune checkpoint inhibitorsradiotherapytreatment optimization

Autor:innen und Institutionen

  • Center of PRaG Therapy, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou 215025, China.
  • Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Affiliated Hospital of Soochow University, Suzhou 215025, China.
  • Jiangsu Key Laboratory of Radiation Injury Prevention and Hazardous Substance Control, Suzhou 215123, China.
  • Jiangsu Nuclear Power Corporation, Lianyungang 222042, China.

Förderung

  • National Natural Science Foundation of China
  • State Key Laboratory of Radiology and Radiation Protection of Soochow University
  • New medical technology project of the Second Affiliated Hospital of Soochow University
  • Multi-center Clinical Research Project for Major Diseases in Suzhou
  • Suzhou Applied Basic Research (Medical and Health) Science and Technology Innovation Project
  • CNNC Medical Nuclear Medicine Technology Innovation Program Project
  • the Subject construction support project of the Second Affiliated Hospital of Soochow University
  • the Pioneer Talent Program of the Second Affiliated Hospital of Soochow University

Zitieren

APA

Xu, M., Yin, J., Li, Y., & Zhang, L. (2026). Antibody–Drug Conjugates Plus Immune Checkpoint Inhibitors for Sustained Disease Control in Advanced Solid Tumors. Cancers, 18(21), 3564. https://doi.org/10.3390/cancers18213564

Vancouver

Xu M, Yin J, Li Y, Zhang L. Antibody–Drug Conjugates Plus Immune Checkpoint Inhibitors for Sustained Disease Control in Advanced Solid Tumors. Cancers. 2026;18(21):3564. doi:10.3390/cancers18213564

BibTeX
@article{Xu2026,
  author = {Xu, Meiling and Yin, Jun and Li, Yao and Zhang, Liyuan},
  title = {Antibody–Drug Conjugates Plus Immune Checkpoint Inhibitors for Sustained Disease Control in Advanced Solid Tumors},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3564},
  doi = {10.3390/cancers18213564}
}
Kostenlos starten →